Penbrook Management LLC Sells 150,175 Shares of Mesoblast Limited (NASDAQ:MESO)

Penbrook Management LLC lowered its stake in Mesoblast Limited (NASDAQ:MESO) by 54.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,175 shares of the company’s stock after selling 150,175 shares during the quarter. Penbrook Management LLC owned about 0.11% of Mesoblast worth $627,000 as of its most recent filing with the Securities & Exchange Commission.

Mesoblast Trading Down 4.9 %

Shares of NASDAQ:MESO traded down $0.33 during midday trading on Tuesday, reaching $6.45. 240,067 shares of the company were exchanged, compared to its average volume of 1,215,783. The stock has a market cap of $736.46 million, a PE ratio of -5.71 and a beta of 3.48. The business’s fifty day moving average is $7.25 and its two-hundred day moving average is $4.33. Mesoblast Limited has a one year low of $1.61 and a one year high of $10.24.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on MESO shares. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research note on Thursday, June 20th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.67.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.